Article ; Online: Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
2017 Volume 50, Issue 6, Page(s) 808–813
Abstract: The ECG plays a critical role in the thorough QT study. This clinical study is part of the assessment of proarrhythmic potential of drugs under the current regulatory paradigm. While the current paradigm has been successful in preventing drugs with ... ...
Abstract | The ECG plays a critical role in the thorough QT study. This clinical study is part of the assessment of proarrhythmic potential of drugs under the current regulatory paradigm. While the current paradigm has been successful in preventing drugs with unexpected QT prolongation or torsade risk from reaching the market, the focus on QT prolongation has likely resulted in potentially beneficial compounds with minimal torsade risk being dropped from development. The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is developing and validating a new mechanistic-based paradigm for cardiac safety evaluation of drugs. The fourth component of CiPA uses ECG data in phase 1 clinical studies to confirm there are no unanticipated ion channel effects compared to nonclinical data. The J-Tpeak interval was identified as the best biomarker for differentiating QTc prolonging drugs with predominant hERG block from drugs with multichannel (hERG plus late sodium and/or calcium block). This manuscript describes ECG methods for J-Tpeak assessment and their relationship with the features of new ECG biomarkers for detecting multichannel effects under CiPA. |
---|---|
MeSH term(s) | Algorithms ; Arrhythmias, Cardiac/chemically induced ; Arrhythmias, Cardiac/diagnosis ; Biomarkers/analysis ; Calcium Channel Blockers/pharmacology ; Electrocardiography/methods ; Electrophysiological Phenomena ; Heart Conduction System/drug effects ; Heart Rate/drug effects ; Heart Rate/physiology ; Humans ; Ion Channels/drug effects ; Long QT Syndrome/chemically induced ; Long QT Syndrome/diagnosis ; Phenethylamines/pharmacology ; Potassium Channel Blockers/pharmacology ; Quinidine/pharmacology ; Ranolazine/pharmacology ; Sodium Channel Blockers/pharmacology ; Sulfonamides/pharmacology ; Torsades de Pointes/chemically induced ; Torsades de Pointes/diagnosis ; Verapamil/pharmacology |
Chemical Substances | Biomarkers ; Calcium Channel Blockers ; Ion Channels ; Phenethylamines ; Potassium Channel Blockers ; Sodium Channel Blockers ; Sulfonamides ; Ranolazine (A6IEZ5M406) ; Verapamil (CJ0O37KU29) ; Quinidine (ITX08688JL) ; dofetilide (R4Z9X1N2ND) |
Language | English |
Publishing date | 2017-11 |
Publishing country | United States |
Document type | Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S. |
ZDB-ID | 410286-1 |
ISSN | 1532-8430 ; 0022-0736 |
ISSN (online) | 1532-8430 |
ISSN | 0022-0736 |
DOI | 10.1016/j.jelectrocard.2017.08.003 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 701: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.